(RVMD) Revolution Medicines - Overview

Sector: HealthcareIndustry: Biotechnology | Exchange NASDAQ (USA) | Currency USD | Market Cap: 18.930m | Total Return 161.6% in 12m

Stock Cancer Therapies, Drug Development, Oncology Drugs, Targeted Treatments
Total Rating 41
Risk 72
Buy Signal -0.57
Biotechnology -5.1
Biotechnology -4.3
Market Cap: 18,930m
Avg Trading Vol: 164M USD
ATR: 3.80%
Peers RS (IBD): 82.8
Risk 5d forecast
Volatility45.1%
Rel. Tail Risk-13.1%
Reward TTM
Sharpe Ratio1.80
Alpha134.59
Character TTM
Beta0.751
Beta Downside0.386
Drawdowns 3y
Max DD48.63%
CAGR/Max DD1.30
EPS (Earnings per Share) EPS (Earnings per Share) of RVMD over the last years for every Quarter: "2021-03": -0.53, "2021-06": -0.6, "2021-09": -0.72, "2021-12": -0.71, "2022-03": -0.78, "2022-06": -0.82, "2022-09": -0.87, "2022-12": -0.63, "2023-03": -0.72, "2023-06": -0.92, "2023-09": -0.99, "2023-12": -1.14, "2024-03": -0.7, "2024-06": -0.81, "2024-09": -0.94, "2024-12": -1.12, "2025-03": -1.13, "2025-06": -1.31, "2025-09": -1.61, "2025-12": -1.86,
EPS CAGR: -49.13%
EPS Trend: -79.1%
Last SUE: -2.05
Qual. Beats: 0
Revenue Revenue of RVMD over the last years for every Quarter: 2021-03: 10.131, 2021-06: 8.698, 2021-09: 1.101, 2021-12: 9.46, 2022-03: 7.578, 2022-06: 9.116, 2022-09: 3.356, 2022-12: 15.33, 2023-03: 7.014, 2023-06: 3.824, 2023-09: 0, 2023-12: 0.742, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 261.592, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: 0,
Rev. CAGR: -75.82%
Rev. Trend: -44.5%
Last SUE: -0.41
Qual. Beats: 0
Description: RVMD Revolution Medicines March 05, 2026

Revolution Medicines, Inc. (RVMD) is a clinical-stage biotechnology company focused on developing targeted therapies for RAS-addicted cancers.

The companys pipeline includes RAS(ON) inhibitors, such as daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), all in Phase 1 clinical trials. These inhibitors target specific RAS variants. Additionally, RVMD is developing RAS companion inhibitors like RMC-4630 (Phase 2) and RMC-5552 (Phase 1), which aim to suppress pathways that support RAS-addicted cancers. The biotechnology sector is characterized by lengthy and expensive research and development cycles.

RVMDs business model centers on the discovery and clinical development of novel oncology drugs, with potential for future commercialization or partnerships.

For more detailed financial and operational data, ValueRay offers comprehensive company profiles.

Headlines to Watch Out For
  • Clinical trial results for RAS(ON) inhibitors drive stock volatility
  • Regulatory approval of lead drug candidates critical for revenue
  • Collaboration milestones with Aventis impact financial outlook
  • Competition in RAS-addicted cancer market affects future sales
  • Research and development expenses remain significant cost factor
Piotroski VR‑10 (Strict, 0-10) 0.0
Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.39 > 0.02 and ΔFCF/TA -16.62 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.38 > 3% & CFO -897.7m > Net Income -1.13b
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 7.14 > 1.5 & < 3
Outstanding Shares: last quarter (190.1m) vs 12m ago 13.35% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 10.23%; Δ -10.23% > 0%)
Interest Coverage Ratio: -47.49 > 6 (EBITDA TTM -1.14b / Interest Expense TTM 24.3m)
Altman Z'' -6.31
A: 0.76 (Total Current Assets 2.08b - Total Current Liabilities 290.4m) / Total Assets 2.35b
B: -1.22 (Retained Earnings -2.87b / Total Assets 2.35b)
C: -0.47 (EBIT TTM -1.15b / Avg Total Assets 2.46b)
D: -3.96 (Book Value of Equity -2.87b / Total Liabilities 723.2m)
Altman-Z'' Score: -6.31 = D
Beneish M
DSRI: none (Receivables none/none, Revenue 0.0/261.6m)
GMI: 1.00 (fallback, negative margins)
AQI: 1.40 (AQ_t 0.05 / AQ_t-1 0.03)
SGI: none (Revenue 0.0 / 261.6m)
TATA: -0.10 (NI -1.13b - CFO -897.7m) / TA 2.35b)
Beneish M-Score: cannot calculate (missing components)
What is the price of RVMD shares? As of March 30, 2026, the stock is trading at USD 92.51 with a total of 1,102,734 shares traded.
Over the past week, the price has changed by -4.26%, over one month by -9.32%, over three months by +14.89% and over the past year by +161.62%.
Is RVMD a buy, sell or hold? Revolution Medicines has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy RVMD.
  • StrongBuy: 8
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the RVMD price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 133.7 44.5%
Analysts Target Price 133.7 44.5%
RVMD Fundamental Data Overview March 26, 2026
P/S = 9035.0954
P/B = 11.6428
Revenue TTM = 0.0 USD
EBIT TTM = -1.15b USD
EBITDA TTM = -1.14b USD
Long Term Debt = 158.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 16.5m USD (from shortTermDebt, last quarter)
Debt = 158.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -225.0m USD (from netDebt column, last quarter)
Enterprise Value = 17.06b USD (18.93b + Debt 158.7m - CCE 2.03b)
Interest Coverage Ratio = -47.49 (Ebit TTM -1.15b / Interest Expense TTM 24.3m)
EV/FCF = -18.67x (Enterprise Value 17.06b / FCF TTM -913.7m)
FCF Yield = -5.36% (FCF TTM -913.7m / Enterprise Value 17.06b)
 FCF Margin = unknown (Revenue TTM is 0 or missing)
 Net Margin = unknown
 Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 214.3m) / Revenue TTM)
 Tobins Q-Ratio = 7.25 (Enterprise Value 17.06b / Total Assets 2.35b)
Interest Expense / Debt = 7.52% (Interest Expense 11.9m / Debt 158.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -910.2m (EBIT -1.15b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.14 (Total Current Assets 2.08b / Total Current Liabilities 290.4m)
Debt / Equity = 0.10 (Debt 158.7m / totalStockholderEquity, last quarter 1.63b)
 Debt / EBITDA = 0.20 (negative EBITDA) (Net Debt -225.0m / EBITDA -1.14b)
 Debt / FCF = 0.25 (negative FCF - burning cash) (Net Debt -225.0m / FCF TTM -913.7m)
 Total Stockholder Equity = 1.79b (last 4 quarters mean from totalStockholderEquity)
RoA = -46.06% (Net Income -1.13b / Total Assets 2.35b)
RoE = -63.10% (Net Income TTM -1.13b / Total Stockholder Equity 1.79b)
RoCE = -59.04% (EBIT -1.15b / Capital Employed (Equity 1.79b + L.T.Debt 158.7m))
 RoIC = -50.77% (negative operating profit) (NOPAT -910.2m / Invested Capital 1.79b)
 WACC = 8.60% (E(18.93b)/V(19.09b) * Re(8.62%) + D(158.7m)/V(19.09b) * Rd(7.52%) * (1-Tc(0.21)))
Discount Rate = 8.62% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 16.05%
 [DCF] Fair Price = unknown (Cash Flow -913.7m)
 EPS Correlation: -79.09 | EPS CAGR: -49.13% | SUE: -2.05 | # QB: 0
Revenue Correlation: -44.51 | Revenue CAGR: -75.82% | SUE: -0.41 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.89 | Chg7d=-0.000 | Chg30d=-0.189 | Revisions Net=-5 | Analysts=16
EPS current Year (2026-12-31): EPS=-7.61 | Chg7d=-0.006 | Chg30d=-1.077 | Revisions Net=-12 | Growth EPS=-27.9% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-6.74 | Chg7d=-0.068 | Chg30d=-0.826 | Revisions Net=-3 | Growth EPS=+11.5% | Growth Revenue=+676.5%
[Analyst] Revisions Ratio: -0.71 (1 Up / 6 Down within 30d for Next Quarter)
Additional Sources for RVMD Stock Fund Manager Positions: Dataroma · Stockcircle